Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of DPPE Combined With Epirubicin and Cyclophosphamide vs Epirubicin and Cyclophosphamide Alone as First Line Treatment in Metastatic/Recurrent Breast Cancer

NCT00099281 is registered in ClinicalTrials.gov with YM BioSciences as lead sponsor.

NCT NCT00099281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00099281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of DPPE Combined With Epirubicin and Cyclophosphamide vs Epirubicin and Cyclophosphamide Alone as First Line Treatment in Metastatic/Recurrent Breast Cancer
Lead sponsor
YM BioSciences
Phase
Phase 3
Overall status
Terminated
Start date
May 31, 2004
Completion date
June 30, 2006
Enrollment
700
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastases